DBV Technologies' June 23, 2015 Combined Shareholders' Meeting
(Thomson Reuters ONE) -
Regulated Information
Bagneux, France, June 23, 2015
DBV Technologies' June 23, 2015 Combined Shareholders' Meeting
Adoption of all resolutions submitted to the vote of Shareholders
DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - NASDAQ: DBVT), a
biopharmaceutical company, held today its Combined Shareholders' Meeting, which
was chaired by Pierre-Henri Benhamou, the Company's Chairman and Chief Executive
Officer, in presence of the Company's the Board of Directors and Executive
Committee.
At the Combined Meeting, the Company's shareholders approved all the resolutions
submitted by the Board of Directors. These resolutions can be found on DBV's
website under the "Investor Relations" section.
During the Meeting, Pierre-Henri Benhamou, Chairman and Chief Executive Officer,
and David Schilansky, Chief Operating Officer, presented the major events and
financial results for 2014 as well as the most important events since the
beginning of 2015.
About DBV Technologies
DBV Technologies is developing Viaskin®, an innovative new approach to the
treatment of allergies - a major public health issue that has been increasing in
prevalence. DBV Technologies, incorporated in France in 2002, has developed a
proprietary, patented technology for administering an allergen to intact skin
while avoiding transfer to the blood, and thus lowering the risk of a systemic,
allergic reaction in the event of accidental exposure. DBV Technologies is
focusing on food allergies, including milk and peanut, for which there are
currently no effective treatments. DBV Technologies has designed two products
candidates: Viaskin® Peanut and Viaskin® Milk. The clinical development program
for Viaskin® Peanut has received Fast Track designation and Breakthrough Therapy
designation from the U.S. Food and Drug Administration.
DBV Technologies shares are traded on segment B of Euronext Paris (Ticker: DBV,
ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of American
Depositary Shares (each representing one-half of one ordinary share) (Ticker:
DBVT). For more information on DBV Technologies, please visit our website:
www.dbv-technologies.com
Disclaimer
This press release contains forward-looking statements, including statements
about the potential safety and efficacy of Epicutaneous Immunotherapy (EPIT®)
via Viaskin® Peanut and the regulatory pathway afforded by Breakthrough Therapy
designation by the U.S. Food and Drug Administration, which does not change the
standards for approval and is not a guarantee of success. These forward-looking
statements are not promises or guarantees and involve substantial risks and
uncertainties. The Company's product candidates have not been approved for sale
in any jurisdiction. Among the factors that could cause actual results to
differ materially from those described or projected herein are uncertainties
associated generally with research and development, clinical trials and related
regulatory reviews and approvals, the risk that historical preclinical results
may not be predictive of future clinical trial results, and the risk that
historical clinical trial results may not be predictive of future trial
results. A further list and description of these risks, uncertainties and other
risks can be found in the Company's regulatory filings with the French Autorité
des Marchés Financiers, the Company's Securities and Exchange Commission filings
and reports, including in the Company's Annual Report on Form 20-F for the year
ended December 31, 2014, and future filings and reports by the Company.
Existing and prospective investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date hereof. DBV
Technologies undertakes no obligation to update or revise the information
contained in this Press Release, whether as a result of new information, future
events or circumstances or otherwise.
DBV Technologies Contacts
Nathalie Donne Susanna Mesa
Director, Corporate Communication & VP Finance, US Investor Relations &
Business Development Strategy
Tél. : +33(0)1 55 42 78 72 Tél. : +1 917-346-3447
nathalie.donne(at)dbv-technologies.com susanna.mesa(at)dbv-technologies.com
DBV Technologies Media Contacts
Marion Janic
Rooney & Associates
Tél. : +1-212-223-4017
mjanic(at)rooneyco.com
AGM 2015_VA:
http://hugin.info/156437/R/1930428/693825.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: DBV Technologies via GlobeNewswire
[HUG#1930428]
Unternehmensinformation / Kurzprofil:
Datum: 23.06.2015 - 11:00 Uhr
Sprache: Deutsch
News-ID 402281
Anzahl Zeichen: 5726
contact information:
Town:
Bagneux
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 162 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DBV Technologies' June 23, 2015 Combined Shareholders' Meeting"
steht unter der journalistisch-redaktionellen Verantwortung von
DBV Technologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
